Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
Company Directory
Aethlon Medical
3030 Bunker Hill Street, Suite 4000
San Diego
CA 92109
Aethlon Medical is the developer of the Hemopurifier, a medical device to treat infectious disease.

The Hemopurifier addresses the treatment of drug and vaccine resistant viruses.

Regulatory and commercialisation initiatives in the USA are focused on bioterror threats, while international initiatives are directed towards naturally evolving pandemic threats, and chronic infectious disease conditions including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV).
Milestone reached in MERS-COV validation
14 October, 2016
DARPA provides validation on the Aethlon Hemopurifier for capturing the Middle East Respiratory Syndrome Coronavirus
Zika virus study data available
26 August, 2016
Data from Aethlon Medical from n vitro studies made on the zika virus show effectiveness of Hemopurifier product
Study commences on chronic disease caused by trauma
21 January, 2016
The detection and diagnosis of chronic traumatic encephalopathy associated with sports and military injuries is the subject of a new clinical study by Aethlon Medical
First patient trial concluded on Hemopurifier
02 March, 2015
Feasibility study for the FDA concludes first patient treatment with no bad effects relating to the device using the Aethlon Medical Hemopurifier
Researchers make inroads in early cancer detection
21 March, 2014
Aethlon Medical expands brain research discoveries to include isolation of glioblastoma biomarker and therapeutic target
Brain-specific biomarker isolation
10 March, 2014
Researchers have made progress in brain research with the isolation of biomarkers which are associated with degenerative disorders
Agreement reached on Hemopurifier study support
27 February, 2014
Authlon Medical and DaVita Clinical Research reach an agreement on the provision of clinical management services relating to Hemopurifier studies
Presentation on FDA clearance study of hemopurifier
08 January, 2014
CEO of Aethlon Medical is attending the Biotech Showcase 2014 with a presentation on the Aethlon Hemopurifier
Immunotherapy emerging as major cancer treatment
29 October, 2013
Aethlon Medical responds to article on the use of immunotherapy in the battle against malignant tumours
Haemopurification company expansion overseas
16 October, 2013
Aethlon Medical gains ground in the development and roll-out of haemopurification therapy worldwide
Haemopurification system for US defence agency
27 September, 2013
Aethlon is continuing to provide dialysis equipment for use by US defence agencies for the treatment of soldiers
Subsidiary group to focus on study of exosomes
13 September, 2013
Exosome Sciences to be involved in the diagnostics of serious diseases with the detection and analysis of exosomes in body fluids
Presentation to address extracorporeal elimination of circulating exosomes
06 September, 2013
Aethon Medical is attending the Exosomes and Circulating Biomarkers Summit with a presentation on the elimination of circulating exosomes in treating HCV and cancer
Aethlon Medical receives FDA approval of IDE to treat Hepatitis C patients
27 June, 2013
The United States Food and Drug Administration (FDA) approves an Investigational Device Exemption (IDE) that allows Aethlon Medical to initiate human feasibility studies of the Aethlon Hemopurifier in the USA.
Aethlon Medical renews DARPA dialysis-like therapeutics contract
23 August, 2012
The Defense Advanced Research Projects Agency (DARPA) is exercising an option agreement to proceed with year-two of a five-year $6.8 million contract that was awarded to Aethlon Medical on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) programme.
Aethlon Medical expands access to Hemopurifier therapy for Hepatitis C Virus
13 August, 2012
Aethlon Medical is to establish a treatment programme that will provide HCV-infected individuals with expanded access to Hemopurifier therapy.
Aethlon Medical reveals HIV-AIDS research discovery
15 December, 2011
Researchers from Morehouse School of Medicine are showing that the Aethlon Hemopurifier is able to capture particles known as Nef protein exosomes, which contribute to the progression of human immunodeficiency virus (HIV) infection to acquired immunodeficiency syndrome (AIDS).
Cancer research study to target tumour-secreted exosomes
07 December, 2011
Aethlon Medical is reporting that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumour-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California, USA.
Aethlon Medical receives DARPA contract sepsis therapeutic device
04 October, 2011
Aethlon Medical is awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.
Aethlon Medical reveals therapeutic device strategy for breast cancer
21 September, 2011
Aethlon Medical is introduicng HER2osome, a novel medical device strategy to inhibit the progression of HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein.
Aethlon Medical partners Sarcoma to implement cancer studies
25 August, 2011
Aethlon Medical, the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, enters into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.
Aethlon validates assay to identify the presence of exosomes in HIV and TB
14 April, 2011
Aethlon Medical's wholly owned subsidiary Exosome Sciences (ESI) validates the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and various forms of cancer, including ovarian, melanoma, breast, lymphoma, and colorectal.
Aethlon’s Hemopurifier medical device is cleared to be exported to India
09 March, 2011
The US Food and Drug Administration (FDA) grants Aethlon’s request to export its Hemopurifier medical device to India.
Study shows benefits of therapeutic filtration devices for colorectal cancer treament
21 December, 2010
Aethlon Medical, the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, is demonstrating the ability to capture immunosuppressive exosomes derived from individuals with lymphoma and colorectal cancer.
Medicity approves new chronic HCV Infection treatment programme
31 August, 2010
The Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) approves a treatment programme entitled: 'Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy.'
Aethlon Medical reveals Exosome Detection Assay
09 July, 2010
Aethlon Medical is filing a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.
Clinical data presentation on use of Hemopurifier for HCV infected patients
16 October, 2009
Principal investigator of studies on the use of Aethlon’s Hemopurifier to travel to San Diego to present results at the American Society of Nephrology conference
Hemopurifier relationship established with Kentucky Bioprocessing
23 September, 2009
Commercial production deal between Aethlon Medical and Kentucky Bioprocessing for Hemopurifier immobilised active affinity agents
Swine-flu research increases stock market visibility of Aethlon Medical
11 September, 2009
RedChip predicts share price increase at Aethlon Medical due to its work on blood filtering technology leading to valuable swine-flu related information
Aethlon releases data on Hemopurifier’s ability to treat HIV
06 May, 2009
Aethlon Medical releases new data resulting from its recent ′first-in-human’ application of the Aethlon Hemopurifier to treat Human Immunodeficiency Virus (HIV), the disease that causes Acquired Immune Deficiency Syndrome (AIDS).
Aethlon proposes Hemopurifier as a treatment candidate for H1N1virus
05 May, 2009
Aethlon Medical confirms the Aethlon Hemopurifier is a candidate to treat the H1N1 Swine flu virus.
Clinical data shows medical device increases Hepatitis-C cure rates
26 March, 2009
New clinical data supports the advancement of the Aethlon Hemopurifier as an adjunct therapy to increase Hepatitis-C (HCV) cure rates.
Aethlon Medical completes trial of HIV therapeutic filtration device
26 January, 2009
Aethlon Medical has completed the 'first-in-man' study of a medical device designed to treat Human Immunodeficiency Virus (HIV).
Aethlon Medical and Delcath Systems collaborate to develop advanced blood filtration cartridge
31 January, 2008
Aethlon Medical and Delcath Systems have agreed to collaborate on research and development of an advanced filtration cartridge for potential use in Delcath Systems’ percutaneous hepatic perfusion (PHP) system.
Aethlon Medical to collaborate on bird flu research
27 September, 2007
Aethlon Medical is to begin research studies to test the in vitro effectiveness of the Aethlon Hemopurifier to capture H5N1 Avian Influenza.
Aethlon Medical extends cancer research studies
19 September, 2007
Further studies have been initiated by Aethlon Medical to support the use of its Hemopurifier technology in cancer care.
Delhi based Fortis Hospital receives Aethlon Medical’s Hemopurifier shipments
05 September, 2007
Aethlon Medical has shipped Hemopurifier treatment cartridges to support a clinical study to be conducted at the Fortis Hospital in Delhi, India.
Aethlon Medical’s new cancer treatment proves effective
18 July, 2007
Aethlon Medical has discovered the Aethlon Hemopurifier is effective in capturing particles that suppress the immune response in cancer patients.
Aethlon Medical begins clinical testing of Hemopurifier
28 June, 2007
Aethlon Medical is to start clinical testing of the Hemopurifier in human studies to be conducted at the Fortis Hospital in Delhi, India.
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo